Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1177/03331024241269735 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The global epidemiology and health burden of the autism spectrum: findings from the Global Burden of Disease Study 2021.
Lancet Psychiatry
December 2024
Background: High-quality estimates of the epidemiology of the autism spectrum and the health needs of autistic people are necessary for service planners and resource allocators. Here we present the global prevalence and health burden of autism spectrum disorder from the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2021 following improvements to the epidemiological data and burden estimation methods.
Methods: For GBD 2021, a systematic literature review involving searches in PubMed, Embase, PsycINFO, the Global Health Data Exchange, and consultation with experts identified data on the epidemiology of autism spectrum disorder.
Effectiveness of Tecovirimat in Mpox Cases: A Systematic Review of Current Evidence.
J Med Virol
December 2024
SR Sanjeevani Hospital, Kalyanpur, Siraha, Nepal.
Mpox, formerly known as monkeypox, has re-emerged as a significant global health concern, particularly during the widespread outbreak of 2022. As an orthopoxvirus related to the eradicated smallpox virus, mpox has been primarily managed with smallpox vaccines and treatments, including the antiviral agent Tecovirimat. This systematic review aims to evaluate the effectiveness and safety of Tecovirimat in treating mpox, focusing on its use during the 2022 outbreak, especially among high-risk populations, including men who have sex with men and people living with HIV.
View Article and Find Full Text PDFPrevalence of physical and mental health problems among internally displaced persons in White Nile state, Sudan 2023: a cross sectional study.
BMC Public Health
December 2024
Faculty of Medicine, University of Khartoum, Khartoum, Sudan.
Background: Following the latest war in 2023, over nine million people have been internally displaced, of which White Nile State received over 50,000. They lived in different camps and moved to big cities. This study assessed the scope of mental and physical concerns among the IDPs to identify important healthcare needs.
View Article and Find Full Text PDFInterictal burden in migraine patients at the outset of CGRP monoclonal antibody prevention.
J Headache Pain
December 2024
Eli Lilly and Company, Indianapolis, IN, USA.
Background: The total burden of migraine includes not only the episodes with headache pain but extends throughout the interictal periods. Interictal symptoms and associated psychological responses may profoundly impact well-being and drive treatment-seeking behavior.
Methods: A cross-sectional online survey was conducted with participants aged ≥ 18 years, 250 with episodic migraine (EM) and 250 with chronic migraine (CM), having ≥ 4 monthly migraine headache days.
Impact of eptinezumab on work productivity beyond reductions in monthly migraine days: post hoc analysis of the DELIVER trial.
J Patient Rep Outcomes
December 2024
NIHR King's Clinical Research Facility and Headache Group, King's College, London, UK.
Background: Eptinezumab's impact on self-reported work productivity in adults with migraine and 2‒4 prior preventive migraine treatment failures is not fully understood.
Methodology: Electronic diaries captured monthly migraine days (MMDs) reported by patients enrolled in the randomized, double-blind, placebo-controlled DELIVER trial (NCT04418765). The migraine-specific Work Productivity and Activity Impairment questionnaire, administered at baseline and each monthly visit, was a secondary outcome of DELIVER and used to model changes from baseline in self-reported monthly hours of absenteeism (decreased work attendance) and presenteeism (reduced work efficiency while at work with a migraine) in Canada, as the base case.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!